【摘要】 目的 探讨树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)联合化疗对晚期结直肠癌的疗效。方法 回顾性分析42例行DCCIK细胞疗法联合化疗的晚期结直肠癌患者的临床资料,采用1:1配对的方法,选择同期单独行化疗的42例晚期结直肠癌患者作为对照组。对两组的有效率(RR)、疾病控制率(DCR)、生存期及无疾病进展时间进行观察比较。结果 DC-CIK治疗组患者的疾病控制率(DCR)明显高于化疗组(76.19%VS 52.38%),差异有统计学意义(P<0.05);治疗组的中位生存期明显高于化疗组(17.5个月VS 13.3个月),差异有统计学意义(P=0.008)。结论 DC-CIK细胞联合化疗可以明显提高晚期结直肠癌患者的疾病控制率,延长生存期。更多还原

【Abstract】 Objective To evaluate the effect of DC-CIK adoptive immunotherapy combined with chemotherapy in the treatment of advanced colorectal cancer.Methods We retrospectively analyzed 42 patients of advanced colorectal cancer treated with DC-CIK adoptive immunotherapy combined with chemotherapy and choose 42 patients at the same period as control treated only with chemotherapy.The response rate(RR),disease control rate(DCR),median overall survival time and progression-free survival time were investigated and compared between the two groups.Results The disease control rate in the DC-CIK treatment group was significantly higher than that in the chemotherapy group(76.19%VS 52.38%),and the difference was statistically significant(P<0.05).The median overall survival time in the DC-CIK treatment group was significantly longer than that in the chemotherapy group(17.5 VS 13.3months),and the difference was statistically significant(P=0.008).Conclusion DC-CIK adoptive immunotherapy combined with chemotherapy could significantly improve the disease control rate and the overall survival time of patients with advanced colorectal cancer.更多还原